← Leaderboards
Janice G Mc Farland
Bloodcenter Of Wisconsin, Inc.
$2,072,071
Attributed
$2,072,071
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $300K · FY2005–12$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$2,072,071 · 1
By mechanism
U01$2,072,071 · 1
Top collaborators
No co-investigators on record.
Most similar at Bloodcenter Of Wisconsin, Inc.
Same institution · by research overlap
- Peter J Newman$21,473,700
- Richard Herbert Aster$12,040,804
- Demin Wang$12,080,022
- Julie A Peterson$367,057
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsRelapse /RecurrenceIsoantibodyAreaBlood Component RemovalBlood TreatmentBlood PlateletsGillsClinical Trials NetworkCooperative StudyCorticosteroidsBlood TransfusionDoseEnrollmentFundingClinical ResearchBlood Disorder ChemotherapyGranulocyteHemophilia AHemorrhageHemostasisHemostatic FunctionHistocompatibilityAward
Grant awards (8)
TMH Clinical Trials Network-Wisconsin Core Clinical Center$195,370
U01 · FY2012 · HL · contact PI
TMH Clinical Trials Network-Wisconsin Core Clinical Center$191,875
U01 · FY2009 · HL · contact PI
TMH Clinical Trials Network-Wisconsin Core Clinical Center$191,875
U01 · FY2007 · HL · contact PI
Optimizing Treatment for TTP and Platelet Refractoriness$292,951
U01 · FY2006 · HL · contact PI
Optimizing Treatment for TTP and Platelet Refractoriness$300,000
U01 · FY2005 · HL
Optimizing Treatment for TTP and Platelet Refractoriness$300,000
U01 · FY2004 · HL
Optimizing Treatment for TTP and Platelet Refractoriness$300,000
U01 · FY2003 · HL
Optimizing Treatment for TTP and Platelet Refractoriness$300,000
U01 · FY2002 · HL